ENSC
Ensysce Biosciences, Inc.
$0.28
-0.02 (-6.44%)
At close · Jul 7
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$4.04M
Shares
14,694,492
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Lynn Kirkpatrick | CEO | $442,392 |
| Dave Humphrey | CFO | $371,267 |
| Geoff Birkett | — | $343,634 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Lynn Kirkpatrick | CEO | $508,575 |
| Dave Humphrey | — | $441,950 |
| Geoff Birkett | — | $392,354 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Dave Humphrey | — | $780,617 |
| Lynn Kirkpatrick | CEO | $622,609 |
| Geoff Birkett | — | $366,956 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Lynn Kirkpatrick | CEO | $288,149 |
| Geoff Birkett | — | $135,000 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Lynn Kirkpatrick | CEO | $155,868 |
| Richard Wright | — | $76,000 |
| Geoff Birkett | — | $72,000 |